These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 12756819)

  • 1. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(24):5551-2. PubMed ID: 14968802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drugs in Europe].
    Bouzy C; Abadie E
    Rev Prat; 2002 Mar; 52(5):510-4. PubMed ID: 11949504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Registration of new medicinal products in Europe].
    Singer E
    Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Europe and medicines: role of the EMEA].
    Sauer F
    Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [European network for investigation of medicinal products in children (Medichildren)].
    Pons G
    Arch Pediatr; 2006 Jun; 13(6):631. PubMed ID: 16713209
    [No Abstract]   [Full Text] [Related]  

  • 13. [Network for investigation of medicinal products in children].
    Kassaï B; Treluyer JM; Jacqz-Aigrain E; Pons G
    Arch Pediatr; 2006 Jun; 13(6):631-4. PubMed ID: 16697606
    [No Abstract]   [Full Text] [Related]  

  • 14. [National and European drug approval procedures].
    Mohrbutter KP
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):593-6. PubMed ID: 9527447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH); final guidance for industry on "studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing" (VICH GL23); availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(3):602-3. PubMed ID: 12358039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.